ABVC Biopharma Files Definitive Additional Materials
Ticker: ABVC · Form: DEFA14A · Filed: Mar 25, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | DEFA14A |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 19 min |
| Key Dollar Amounts | $1,200,000, $1,000,000, $3.50, $2, $8333,333 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
TL;DR
ABVC filed extra proxy docs, no fee. Shareholders get more info.
AI Summary
ABVC Biopharma, Inc. filed definitive additional materials on March 25, 2024, related to its proxy statement. The filing concerns the company's Schedule 14A, which is a proxy statement used for shareholder meetings. No fee was required for this filing.
Why It Matters
This filing provides shareholders with important supplemental information regarding the company's proxy statement, which is crucial for understanding upcoming shareholder votes and corporate governance matters.
Risk Assessment
Risk Level: low — This filing is administrative in nature, providing additional materials for a proxy statement, and does not contain new financial or operational information that would inherently increase risk.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- 0001213900-24-025561.txt (document) — Filing document identifier
- 20240325 (date) — Filing date
- Schedule 14A (document) — Proxy Statement form type
FAQ
What type of filing is this for ABVC Biopharma, Inc.?
This is a Definitive Additional Materials filing for a Schedule 14A Proxy Statement.
When was this filing made?
The filing was made on March 25, 2024.
Is there a fee associated with this filing?
No fee was required for this filing.
What is the purpose of a Schedule 14A filing?
A Schedule 14A filing is a Proxy Statement filed with the SEC, typically used to solicit shareholder votes on important corporate matters.
What was ABVC Biopharma's former name?
ABVC Biopharma, Inc. was formerly known as American BriVision (Holding) Corp, METU BRANDS, INC., and ECOLOGY COATINGS, INC. on different dates.
Filing Stats: 4,646 words · 19 min read · ~15 pages · Grade level 14.2 · Accepted 2024-03-25 16:30:23
Key Financial Figures
- $1,200,000 — ertible note in the principal amount of $1,200,000 (the “November Offering”),
- $1,000,000 — fering”), for a purchase price of $1,000,000 (the “November Note”), that
- $3.50 — price, which shall be the lesser of (i) $3.50 (the “Fixed Price”) and (ii
- $2 — n stock at an initial exercise price of $2 per share, subject to adjustment (each,
- $8333,333 — erings”), for a purchase price of $8333,333 (the “January Note,” togeth
- $2.00 — n stock at an initial exercise price of $2.00 per share, subject to adjustment (each,
- $1.00 — both notes shall have a floor price of $1.00 (the “Amendment”). Addition
- $60,155 — and cash equivalents was approximately $60,155. In November 2023 and January 2024, our
- $2.2 m — erings, which yielded gross proceeds of $2.2 million, was necessary in light of our ca
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
- $5.2 — aq Stock Market as of June 30, 2023 was $5.2. As of March 12, 2024, the registrant
Filing Documents
- ea0202391-defa14a_abvcbio.htm (DEFA14A) — 1584KB
- image_001.jpg (GRAPHIC) — 67KB
- image_002.jpg (GRAPHIC) — 20KB
- image_003.jpg (GRAPHIC) — 5KB
- image_004.jpg (GRAPHIC) — 2KB
- 0001213900-24-025561.txt ( ) — 1715KB
Business
Business 3 Item 1A.
Risk Factors
Risk Factors 19 Item 1B. Unresolved staff comments 43 Item 1C. Cybersecurity 43 Item 2.
Properties
Properties 43 Item 3.
Legal Proceedings
Legal Proceedings 43 Item 4. Mine Safety Disclosures 43 Part II Item 5. Market for Registrant’s Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities 44 Item 6. [Reserved] 45 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 45 Item 7A. Quantitative and Qualitativ